Stocktoria
AXIM BIOTECHNOLOGIES, INC. AXIM
OTC · stock · Pharmaceutical Preparations · website · IPO 2013-04-09
AXIM BIOTECHNOLOGIES, INC. (AXIM) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2023 revenue was $39,518 at a -20395.0% net margin.
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$1M
Net margin-20395%
Revenue trend · last 10y · down
How it ranks in Manufacturing · percentile among 1906 companies
Piotroski Fstronger than 27%
Net marginstronger than 2%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
FAQ
Is AXIM financially healthy?
AXIM BIOTECHNOLOGIES, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does AXIM pay a dividend?
No, AXIM BIOTECHNOLOGIES, INC. does not currently pay a dividend.
How profitable is AXIM?
In FY2023, AXIM BIOTECHNOLOGIES, INC. had a net margin of -20395.0%.
Source: SEC EDGAR filings · CIK 0001514946 · US · as of 2023-12-31. facts plus Stocktoria's own computed scores — not investment advice.